In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 43, Issue , 1999, Pages

  Crystal, Ronald G ^a,b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CONFERENCE PAPER; GENE TARGETING; GENE THERAPY; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

EID: 0033060416     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051105     Document Type: Conference Paper

References (107)

1. Andersen L, Kilstrup M, Neuhard J (1989) Pyrimidine, purine and nitrogen control of cytosine deaminase synthesis in Escherichia coli K 12. Involvement of the glnLG and purR genes in the regulation of codA expression. Arch Microbiol 152: 115
2. Anderson WF (1998) Human gene therapy. Nature 392: 25
3. Austin EA, Huber BE (1993) A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol 43: 380
4. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E (1994) Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res 28: 1176
5. Barleon B, Hauser S, Schollmann C, Weindel K, Marme D, Yayon A, Weich HA (1994) Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells. J Cell Biochem 54: 56
6. Bennett J (1998) Antifungal agents. In: Gilman AG, Rall T, Nies AS, Taylor P (eds), Goodman and Gilman's the pharmacological basis of therapeutics. Pergamon Press, New York, p. 1165
7. Bevan MJ (1995) Antigen presentation to cytotoxic T lymphocytes in vivo. J Exp Med 182: 639
8. Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183: 725
9. Bramson JL, Graham FL, Gauldie J (1995) The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr Opin Biotechnol 6: 590
10. Brogi E, Schatteman G, Wu T, Kim EA, Varticovski L, Keyt B, Isner JM (1996) Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest 97: 469
11. Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, Van de Water L (1992) Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176: 1375
12. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP (1996) Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 156: 224
13. Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SLC (1994) Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 91: 3054
14. Connors TA (1995) The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther 2: 702
15. Crystal RG (1995) Transfer of genes to humans: early lessons and obstacles to success. Science 270: 404
16. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550
17. Davis BM, Koc ON, Lee K, Gerson SL (1996) Current progress in the gene therapy of cancer. Curr Opin Oncol 8: 499
18. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989
19. Di Maio JM, Clary BM, Via DF, Coveney E, Pappas TN, Lyerly HK (1994) Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 116: 205
20. Falck-Pedersen E (1998) Use and application of adenovirus expression vectors. In: Spector DL, Goldman RD, Leinwand LA (eds), Cells: a laboratory manual. Cold Spring Harbor Laboratory Press, Plainview, NY
21. Ferrara N, Houck K, Jakeman L, Leung DW (1992) Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13: 18
22. Flanagan B, Pringle CR, Leppard KN (1997) A recombinant adenovirus expressing the simian immunodeficiency virus Gag antigen can induce long-lived immune responses in mice. J Gen Virol 78: 991
23. Folkman J (1995) Tumor angiogenesis. In: Mendelsoh J, Howley PM, Israel MA, Liotta LA (eds), The molecular basis of cancer. W.B. Saunders, Philadelphia, p. 206
24. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1: 27
25. Folkman J, Klagsburn M (1987) Angiogenic factors. Science 235: 442
26. Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267: 10931
27. Folkman J, Cole P, Zimmerman S (1966) Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 164: 491
28. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S (1995) Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 270: 12607
29. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16
30. Germain RN (1994) MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76: 287
31. Grabbe S, Beissert S, Schwarz T, Granstein RD (1995) Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today 16: 117
32. Green NK, Youngs DJ, Neoptolemos JP, Friedlos F, Knox RJ, Springer CJ, Anlezark GM, Michael NP, Melton RG, Ford MJ, Young LS, Kerr DJ, Searle PF (1997) Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther 4: 229
33. Gutierrez AA, Lemoine NR, Sikora K (1992) Gene therapy for cancer. Lancet 339: 715
34. Haddada H, Cordier L, Perricaudet M (1995) Gene therapy using adenovirus vectors. Curr Top Microbiol Immunol 199: 297
35. Hang J, Kong L, Gu JW, Adair TH (1995) VEGF gene expression is upregulated in electrically stimulated rat skeletal muscle. Am J Physiol 269: H1827
36. Heldin CH (1995) Dimerization of cell surface receptors in signal transduction. Cell 80: 213
37. Herz J, Gerard RD (1993) Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol in normal mice. Proc Natl Acad Sci USA 90: 2812
38. Hirschowitz EA, Ohwada A, Pascal WR, Russi TJ, Crystal RG (1995) In vivo adeno virus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 6: 1055
39. Holmgren L, O'Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1: 149
40. Houghton AN (1994) Cancer antigens: immune recognition of self and altered self. J Exp Med 180: 1
41. Huard J, Lochmuller H, Acsadi G, Jani A, Massie B, Karpati G (1995) The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 2: 107
42. Huber BE, Richards CA, Krenitsky TA (1991) Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 88: 8039
43. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA (1993) In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 53: 4619
44. Huber BE, Austin EA, Richards CA, Davis ST, Good SS (1994) Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91: 8302
45. Juillard V, Villefroy P, Godfrin D, Pavirani A, Venet A, Guillet JG (1995) Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur J Immunol 25: 3467
46. Kaneda N, Nagata H, Furuta T, Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715
47. Kaneko S, Hallenbeck P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T, Anderson WF, Chiang YL (1995) Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 55: 5283
48. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187
49. Kendall RL, Thomas KA (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90: 10705
50. Kendall RL, Wang G, Thomas KA (1996) Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226: 324
51. Kilstrup M, Meng LM, Neuhard J, Nygaard P (1989) Genetic evidence for a repressor of synthesis of cytosine deaminase and purine biosynthesis enzymes in Escherichia coli. J Bacteriol 171: 2124
52. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vvo. Nature 362: 841
53. Klagsbrun M, D'Amore PA (1991) Regulators of angiogenesis. Annu Rev Physiol 53: 217
54. Kojima A, Hackett NR, Ohwada A, Crystal RG (1998) In vivo human CE cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest 101: 1789
55. Kong HL, Hecht D, Song W, Kovesdi I, Hackett NR, Yayon A, Crystal RG (1998) Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 9: 823
56. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944
57. Lafreniere R, Rosenberg SA (1986) A novel approach to the generation and identification of experimental hepatic metastases in a murine model. J Natl Cancer Inst 76: 309
58. Lavelle F, Bissery MC, Andre S, Roquet F, Riou JF (1996) Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol 23: 11
59. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306
60. Link CJ Jr, Kolb EM, Muldoon RR (1995) Preliminary in vitro efficacy and toxicities studies of the herpes simplex thymidine kinase gene system for the treatment of breast cancer. Hybridoma 14: 143
61. Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327
62. Manome Y, Wen PY, Dong Y, Tanaka T, Mitchell BS, Kufe DW, Fine HA (1996) Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nature Med 2: 567
63. Marais R, Spooner RA, Light Y, Martin J, Springer CJ (1996) Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase g2 combination. Cancer Res 56: 4735
64. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M (1992) CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225
65. Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR (1991) A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci USA 88: 9026
66. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, Ullrich A (1993) High affinity VEGF binding and developmental expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835
67. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative flk-1 mutant. Nature 367: 576
68. Moolten FL (1994) Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther 1: 279
69. Morrison RS, Yahanda AM (1995) Tumor angiogenesis and the role of paracrine mediators. In: Freireich EJ, Stass SA (eds), Molecular basis of oncology. Blackwell Science, Cambridge, MA, p. 163
70. Mullen CA, Kilstrup M, Blaese RM (1992) Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 89: 33
71. Mullen CA, Coale MM, Lowe R, Blaese RM (1994) Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 54: 1503
72. Mulligan RC (1993) The basic science of gene therapy. Science 260: 926
73. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, Taguchi T (1991) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83: 1164
74. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315
75. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Ito Y, Morishima Y, Yokomaku S, Ota K (1990) An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8: 1907
76. Ohwada A, Hirschowitz EA, Crystal RG (1996) Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. Hum Gene Ther 7: 1567
77. Pardoll DM (1993) Cancer vaccines. Immunol Today 14: 310
78. Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, Neufeld G (1997) VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 272: 7151
79. Quinn TP, Peters KG, de Vries C, Ferrara N, Williams LT (1993) Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 90: 7533
80. Reynolds LP, Killilea SD, Redmer DA (1992) Angiogenesis in the female reproductive system. FASEB J 6: 886
81. Richards CA, Austin EA, Huber BE (1995) Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 6: 881
82. Rigg A, Sikora K (1997) Genetic prodrug activation therapy. Mol Med Today 3: 359
83. Rodriques EG, Zavala F, Eichinger D, Wilson JM, Tsuji M (1997) Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J Immunol 158: 1268
84. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983
85. Senger DR, Perruzzi CA, Feder J, Dvorak HF (1986) A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46: 5629
86. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF (1993) Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12: 303
87. Shenk T (1996) Adenoviridae: The viruses and their replication. In: Fields BN, Knipe DM, Howley PM (eds), Fields virology. Lippincott-Raven Publishers, Inc. Philadelphia, p. 2111
88. Shibuya M (1995) Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 67: 281
89. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M (1990) Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5: 519
90. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N, The CPT-11 Gastrointestinal Cancer Study Group (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11: 909
91. Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843
92. Shweiki D, Neeman M, Itin A, Keshet E (1995) Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 92: 768
93. Smythe WR, Hwang HC, Amin KM, Eck SL, Davidson BL, Wilson JM, Kaiser LR, Albelda SM (1994) Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 54: 2055
94. Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, Moore MA, Crystal RG (1997) Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 186: 1247
95. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271
96. Steinman RM (1997) Dendritic cells and immune-based therapies. Exp Hematol 24: 859
97. Takeuchi S, Takamizawa H, Takeda Y, Ohkawa T, Tamaya T, Noda K, Sugawa T, Sekiba K, Yakushiji M, Taguchi T (1991) An early phase II study of CPT-11 in gynecologic cancers. Research Group of CPT-11 in Gynecologic Cancers. Gan To Kagaku Ryoho 18: 579 (In Japanese)
98. Tanaka T, Kanai F, Okabe S, Yoshida Y, Wakimoto H, Hamada H, Shiratori Y, Lan K, Ishitobi M, Omata M (1996) Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res 56: 1341
99. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187: 1579
100. Thomas KA (1996) Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 271: 603
101. Topf N, Worgall S, Hackett NR, and Crystal RG (1998) Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther 5: 507
102. Tuder RM, Flook BE, Voelkel NF (1995) Increased gene expression for VEGF and the VEGF receptors KDR/flk and fit in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 95: 1798
103. Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, Restifo NP (1995) Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 154: 4685
104. Wilson JM (1996) Adenoviruses as gene-delivery vehicles. N Engl J Med 334: 1185
105. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG (1997) Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 8: 37
106. Xiang ZQ, Yang Y, Wilson JM, Ertl HC (1996) A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219: 220
107. Young JW, Inaba K (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 183: 7